Table 2.
Results of subgroup analysis of Child-Turcotte-Pugh, Model for End-stage Liver Disease score, and Model for End-stage Liver Disease-Na score in predicting mortality at different time points
| End-point (mortality) | Number of studies | Sensitivity (95%CI) | Specificity (95%CI) | Positive (95%CI) | Negative (95%CI) | DOR (95%CI) | I2 | AUROC |
| CTP | ||||||||
| < 3 mo | 8 | 0.72 (0.61, 0.81) | 0.73 (0.65, 0.79) | 2.6 (1.9, 3.7) | 0.39 (0.26, 0.58) | 7 (3, 14) | 0 | 0.78 |
| 3 mo | 5 | 0.79 (0.60, 0.91) | 0.79 (0.59, 0.90) | 3.7 (1.8, 7.6) | 0.26 (0.13, 0.55) | 14 (4, 46) | 96 | 0.86 |
| 6 mo | 3 | 0.90 (0.80, 0.96) | 0.69 (0.64, 0.75) | 3.0 (2.1, 4.5) | 0.16 (0.08, 0.33) | 18 (8, 40) | 0 | 0.91 |
| 12 mo | 3 | 0.68 (0.58, 0.72) | 0.68 (0.64, 0.72) | 3.3 (1.5, 7.3) | 0.49 (0.40, 0.60) | 7 (3, 20) | 84 | 0.72 |
| MELD | ||||||||
| < 3 mo | 9 | 0.66 (0.59, 0.73) | 0.87 (0.81, 0.91) | 5.1 (3.4, 7.7) | 0.39 (0.31, 0.48) | 13 (7, 24) | 6 | 0.76 |
| 3 mo | 6 | 0.70 (0.60, 0.78) | 0.78 (0.65, 0.87) | 3.1 (2.0, 4.9) | 0.39 (0.29, 0.52) | 8 (4, 15) | 95 | 0.78 |
| 6 mo | 3 | 0.74 (0.65, 0.82) | 0.83 (0.79, 0.87) | 4.4 (2.4, 8.2) | 0.30 (0.23, 0.43) | 15 (7, 34) | 56 | 0.83 |
| 12 mo | 4 | 0.60 (0.51, 0.68) | 0.88 (0.79, 0.93) | 4.8 (3.0, 7.7) | 0.46 (0.39, 0.55) | 10 (6, 17) | 92 | 0.75 |
| MELD-Na | ||||||||
| < 3 mo | 4 | 0.82 (0.69, 0.91) | 0.82 (0.64, 0.92) | 4.6 (2.2, 9.8) | 0.21 (0.12, 0.37) | 22 (9, 53) | 89 | 0.89 |
| 3 mo | 4 | 0.75 (0.63, 0.84) | 0.84 (0.80, 0.87) | 4.6 (3.5, 6.0) | 0.30 (0.20, 0.46) | 15 (8, 30) | 0 | 0.86 |
| 6 mo | 3 | 0.82 (0.73, 0.88) | 0.85 (0.80, 0.88) | 5.3 (3.7, 7.7) | 0.22 (0.15, 0.32) | 25 (14, 43) | 0 | 0.90 |
| 12 mo | 3 | 0.72 (0.63, 0.76) | 0.83 (0.80, 0.86) | 4.2 (3.4, 5.1) | 0.37 (0.30, 0.45) | 12 (8, 18) | 0 | 0.84 |
CTP: Child-Turcotte-Pugh; MELD: Model for End-stage Liver Disease score; DOR: Diagnostic odd ratio; AUROC: Area under the summary receiver operating characteristic curve.